Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Rhea-AI Summary
Adial Pharmaceuticals (NASDAQ: ADIL) completed a demonstration batch for AD04 on April 22, 2026, meeting prespecified dissolution, content uniformity, and blend uniformity specifications and matching the Phase 2 dissolution profile. This confirms a successful technical transfer to a new CDMO and enables clinical and registration batch production and IND updates with the FDA.
Positive
- Demonstration batch met dissolution, content, and blend specifications
- Dissolution profile matched prior Phase 2 batch
- Successful technical transfer to a new CDMO
- Enables production of clinical and registration batches for Phase 3 and IND updates
Negative
- None.
News Market Reaction – ADIL
In the Apr 22 session, ADIL declined 1.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Policy supports endpoints | Positive | -25.8% | Congressional directive backing alternative SUD endpoints aligning with AD04 strategy. |
| Sep 16 | EOP2 FDA feedback | Positive | -0.9% | Positive FDA End-of-Phase 2 feedback on Phase 3 design and biomarkers. |
| Sep 03 | Nasdaq bid extension | Neutral | -0.7% | Nasdaq grants 180-day extension to regain minimum bid price compliance. |
| Aug 20 | Senate backs endpoints | Positive | +0.5% | Senate support for expanded clinical endpoints consistent with AD04’s strategy. |
| Jun 11 | Phase 3 planning | Positive | -23.8% | Progress toward Phase 3 using adaptive, data-driven trial design for AD04. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial-related and pathway-strengthening news for AD04 has historically skewed positive in tone but been followed by predominantly negative price moves, indicating a recurring divergence between news flow and market reaction.
Over the past year, Adial has repeatedly advanced the AD04 program with regulatory and clinical milestones. Events included supportive FDA End-of-Phase 2 feedback, advancement toward a Phase 3 adaptive design, and U.S. legislative and policy backing for alternative clinical trial endpoints in substance use disorders. Despite these positives, clinical‑trial‑tagged announcements (e.g., on Feb 4, 2026 and Jun 11, 2025) were often followed by negative price reactions, framing today’s manufacturing and Phase 3-enabling update within a pattern of market skepticism.
Key Terms
dissolution technical
content uniformity technical
blend uniformity technical
clinical-stage technical
biopharmaceutical technical
cdmo technical
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production
GLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the successful completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for the planned Phase 3 clinical batch (and registration campaign) and matched the dissolution profile of the previous Phase 2 batch, thereby demonstrating a successful technical process transfer. This important step was required prior to manufacturing the batch production for the planned Phase 3 clinical program.
The successful tech transfer of the manufacturing and analytical capability for AD04 to a new CDMO resulted in significant efficiencies and crossing the hurdle of dissolution, blend and content uniformity which will have a meaningful clinical and commercial impact for AD04, once approved for patients suffering from AUD.
This successful achievement enables the production of the clinical and registration batches which are required to conduct the clinical trial as well as the needed data for updates to the IND for AD04 with the Food and Drug Administration (FDA).
Cary Claiborne, President and Chief Executive Officer of Adial, commented, “We are continuing to advance the AD04 program and are actively planning for the next phase of our clinical development efforts. The successful completion of the demonstration batch for AD04 positions Adial to effectively progress our plans for the planned clinical trial program, and will assist us with our ongoing discussions with the FDA.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, with no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding transferring the manufacturing and analytical capability for AD04 to a new CDMO having a meaningful clinical and commercial impact for AD04, enabling the production of the clinical and registration batches which are required to conduct the clinical trial as well as the needed data for updates to the IND for AD04 with the Food and Drug Administration, continuing to advance the AD04 program, actively planning for the next phase of the Company’s clinical development efforts, the successful completion of the demonstration batch positioning the Company to effectively progress its plans for the planned clinical trial program, and assisting with its ongoing discussions with the FDA and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
